initial public offerings (IPOs) trading on American exchanges

Thursday, November 19, 2015

Voyager Therapeutics (VYGR) began trading on the Nasdaq on Wed 11 Nov 2015

The clinical-stage gene therapy outfit targets severe diseases of the central nervous system. Parkinson’s disease is one such target, and that is its farthest stage development, along with Genzyme. Voyager’s product pipeline further includes other programs targeting a monogenic form of ALS (amyotrophic lateral sclerosis), Friedreich’s ataxia, Huntington’s disease and spinal muscular atrophy.

Voyager Therapeutics sold 5 million shares at an offering price of $14.00 per share, for gross proceeds of $70 million.

No comments:

Post a Comment